Our Science

Our pipeline

Innovation that advances cancer care

Seagen is developing a new generation of targeted, empowered treatments to advance cancer care. We’ve designed our pipeline with patients in mind, focusing on therapies that have the potential to address significant unmet medical needs.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Seagen Overview Pipeline

Program

Phase

Phase

Brentuximab vedotin (ADCETRIS®)

Learn More
Phase 1
Phase 2
Phase 3

R/R Diffuse large B-Cell lymphoma

ECHELON-3: + lenalidomide, rituximab

1L Hodgkin lymphoma (HL)

+ nivolumab, doxorubicin and dacarbazine

1L HL or PTCL (unfit for combination chemotherapy)

Monotherapy

R/R HL and PTCL

Retreatment

R/R HL (pediatrics)

CheckMate 744: + nivolumab

1L PTCL (< 10% CD30 expression)

+ cyclophosphamide, doxorubicin and prednisone

R/R Metastatic solid tumors

+pembrolizumab post PD-1

Enfortumab vedotin-ejfv (PADCEV®)

Learn More
Phase 1
Phase 2
Phase 3

1L untreated locally advanced or metastatic urothelial cancer

EV-302/KEYNOTE-A39: + pembrolizumab vs chemotherapy alone

Perioperative muscle invasive bladder cancer

KEYNOTE-905/ EV-303: + pembrolizumab, cisplatin ineligible

Perioperative muscle invasive bladder cancer

KEYNOTE-B15/ EV-304: + pembrolizumab, cisplatin eligible

Locally advanced or malignant metastatic solid tumors

EV-202: Monotherapy

Locally advanced or metastatic urothelial cancer*

EV-103/KEYNOTE-869: +/- pembrolizumab

Perioperative muscle invasive bladder cancer

EV-103/KEYNOTE-869: +/- pembrolizumab

BCG unresponsive non-muscle invasive bladder cancer

EV-104: intravesical EV

Tucatinib (TUKYSA®)

Learn More
Phase 1
Phase 2
Phase 3

1L/2L metastatic HER2+ breast cancer

HER2CLIMB-02: + T-DM1

Adjuvant high risk HER2+ breast cancer

COMPASSHER2 RD: +T-DM1**

2L HER2+ metastatic breast cancer

HER2CLIMB-04: + trastuzumab deruxtecan

R/R HER2+ metastatic colorectal cancer*

MOUNTAINEER: + trastuzumab

2L HER2+ gastroesophageal cancer

MOUNTAINEER-02: + trastuzumab, ramucirumab and chemotherapy

Metastatic solid tumors HER2 alterations

+ trastuzumab

1L HER2+ gastric cancer

+ trastuzumab chemotherapy

**The trial is being conducted by the Alliance for Clinical Trials in Oncology

Tisotumab vedotin-tftv (TIVDAK®)

Learn More
Phase 1
Phase 2
Phase 3

2L/3L Metastatic/recurrent cervical cancer

innovaTV 301: Monotherapy vs. chemotherapy

1L/2L Recurrent or metastatic cervical cancer

innovaTV 205: + other anti-cancer agents

R/R Metastatic solid tumors

innovaTV 207: Monotherapy

2L Platinum-resistant ovarian cancer

innovaTV 208: Monotherapy

Disitamab Vedotin

Phase 1
Phase 2
Phase 3

2L HER2 expressing metastatic urothelial carcinoma

RC48 G001: Monotherapy

Ladiratuzumab vedotin

Learn More
Phase 1
Phase 2
Phase 3

1L Metastatic triple-negative breast cancer

+ pembrolizumab

R/R Metastatic solid tumors

Monotherapy

R/R Metastatic breast cancer

Monotherapy

SEA-CD40

Phase 1
Phase 2
Phase 3

Melanoma and NSCLC

+/- other agents

R/R Solid tumors and lymphomas

+/- other agents

SEA-BCMA

Phase 1
Phase 2
Phase 3

R/R Multiple myeloma

+/- other agents

SGN-CD228A

Phase 1
Phase 2
Phase 3

R/R Solid tumors

Monotherapy

SEA-CD70

Phase 1
Phase 2
Phase 3

R/R MDS/AML

Monotherapy

SEA-TGT

Phase 1
Phase 2
Phase 3

R/R Solid tumors and lymphoma

+/- sasanlimab

SGN-B6A

Phase 1
Phase 2
Phase 3

R/R Solid tumors

Monotherapy

SGN-STNV

Phase 1
Phase 2
Phase 3

R/R Solid tumors

Monotherapy

SGN-B7H4V

Phase 1
Phase 2
Phase 3

Advanced solid tumors

Monotherapy

SGN-PDL1V

Phase 1
Phase 2
Phase 3

Advanced solid tumors

Monotherapy

SGN-ALPV

Phase 1
Phase 2
Phase 3

Advanced solid tumors

Monotherapy

In addition to the above programs, our clinical pipeline includes disitamab vedotin, an antibody-drug conjugate that we recently licensed from RemeGen. Disitamab vedotin has potential across multiple HER2-expressing solid tumors, including urothelial, breast and gastric cancers.

1L=frontline/first-line, 2L=second-line, R/R=relapsed/refractory, PTCL=peripheral T-cell lymphoma.
*Enrollment Complete
Pivotal Trial
Top-line Data Reported

Request additional information

Request additional information about an investigational therapy or report an adverse event.

Contact Medical Information
>